U.S. Surgical sees double-digit growth for Valleylab; Pfizer unit acquired for $425 mil. in cash.
This article was originally published in The Gray Sheet
Executive SummaryUSSC EXPANDING ULTRASONIC PRESENCE WITH $425 MIL. PURCHASE OF VALLEYLAB from Pfizer, strengthening U.S. Surgical Corp.'s position in a rapidly growing segment of the surgical products market. During a Dec. 9 teleconference announcing the acquisition, USSC Chairman Leon Hirsch commented that while ultrasonics currently account for a small portion of Valleylab's product offerings, they are "likely to grow a lot faster" than the firm's core business.
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.